Genetic Variation in DNA Repair and Response to Treatment in Esophageal Cancer
Author Information
Author(s): Yoon Harry H, Catalano Paul J, Murphy Kathleen M, Skaar Todd C, Philips Santosh, Powell Mark, Montgomery Elizabeth A, Hafez Michael J, Offer Steven M, Liu Geoffrey, Meltzer Stephen J, Wu Xifeng, Forastiere Arlene A, Benson Al B, Kleinberg Lawrence R, Gibson Michael K
Primary Institution: Mayo Clinic
Hypothesis
The variant allele of the XRCC1 SNP may be associated with resistance to radiochemotherapy in esophageal adenocarcinoma.
Conclusion
The XRCC1 399Gln variant allele is associated with resistance to radiochemotherapy in esophageal adenocarcinoma patients.
Supporting Evidence
- 52% of subjects had the variant allele of the XRCC1 SNP.
- Only 6% of subjects with the variant allele achieved a complete pathologic response (pCR).
- 28% of subjects without the variant allele achieved a pCR.
- The odds ratio for failing to achieve pCR with the variant allele was 5.37.
Takeaway
Some people with a specific gene change don't respond well to cancer treatment, which means doctors might need to find better ways to help them.
Methodology
The study analyzed DNA from 81 treatment-naïve subjects with esophageal adenocarcinoma who received radiotherapy and chemotherapy, focusing on the XRCC1 SNP and its correlation with treatment response.
Limitations
The study's sample size was relatively small, which may affect the statistical significance of the findings.
Participant Demographics
Median age 57 years; 88% male; 93% white.
Statistical Information
P-Value
0.062
Confidence Interval
0.94-57.0
Statistical Significance
p = 0.062
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website